Page 2345 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 140 Hypercoagulable States 2087

REFERENCES 15. Lo GK, Juhl D, Warkentin TE, et al: Evaluation of pretest clinical score
(4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two
1. Vossen CY, Conard J, Fontcuberta J, et al: Risk of a first venous throm- clinical settings. J Thromb Haemost 4(4):759–765, 2006.
botic event in carriers of a familial thrombophilic defect. The European 16. Warkentin TE: Heparin-induced thrombocytopenia. In Marder VJ,
Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost Aird WC, Bennett SC, et al, editors: Hemostasis and thrombosis: basic
3:459, 2005. principles and practice, ed 6, Chapter 108. Philadelphia, 2012, Lippincott
2. Rossi E, Ciminello A, Za T, et al: In families with inherited thrombo- Williams, and Wilkins.
philia the risk of venous thromboembolism is dependent on the clinical 17. Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and
phenotype of the proband. Thromb Haemost 106(4):646–654, 2011. management. Br J Haematol 121:535, 2003.
3. Vossen CY, Walker ID, Svensson P, et al: Recurrence rate after a first 18. Cuker A: Clinical and laboratory diagnosis of heparin-induced thrombo-
venous thrombosis in patients with familial thrombophilia. Arterioscler cytopenia: an integrated approach. Semin Thromb Hemost 40(1):106–114,
Thromb Vasc Biol 25(9):1992–1997, 2005. 2014.
4. Di Minno MN, Dentali F, Lupoli R, et al: Mild antithrombin deficiency 19. Lee AYY: Management of thrombosis in cancer: primary prevention and
and risk of recurrent venous thromboembolism: a prospective cohort secondary prophylaxis. Br J Haematol 128:291, 2006.
study. Circulation 129(4):497–503, 2014. 20. Zamagni E, Brioli A, Tacchetti P, et al: Multiple myeloma, venous
5. Lijfering WM, Brouwer JL, Veeger NJ, et al: Selective testing for throm- thromboembolism, and treatment-related risk of thrombosis. Semin
bophilia in patients with first venous thrombosis: results from a retrospec- Thromb Hemost 37:209, 2011.
tive family cohort study on absolute thrombotic risk for currently known 21. Carrier M, Le Gal G, Lee AYY: Rates of venous thromboembolism
thrombophilic defects in 2479 relatives. Blood 113(21):5314–5322, in multiple myeloma patients undergoing immunomodulatory therapy
2009. with thalidomide or lenalidomide; a systematic review and meta-analysis.
6. Franchi F, Biguzzi E, Martinelli I, et al: Normal reference ranges of J Thromb Haemost 9:653, 2011.
antithrombin, protein C and protein S: effect of sex, age and hormonal 22. Luzzatto L, Gianfaldoni G, Notaro R: Management of paroxysmal
status. Thromb Res 132(2):e152–e157, 2013. nocturnal haemoglobinuria: a personal view. Br J Haematol 153:709,
7. Pintao MC, Ribeiro DD, Bezemer ID, et al: Protein S levels and the risk 2011.
of venous thrombosis: results from the MEGA case-control study. Blood 23. James AH, Jamison MG, Brancazio LR, et al: Venous thromboembolism
122(18):3210–3219, 2013. during pregnancy and the postpartum period: incidence, risk factors, and
8. Vossen CY, Conard J, Fontcuberta J, et al: Familial thrombophilia and mortality. Am J Obstet Gynecol 194:1311, 2006.
lifetime risk of venous thrombosis. J Thromb Haemost 2(9):1526–1532, 24. Middeldorp S: Thrombosis in women: what are the knowledge gaps in
2004. 2013? J Thromb Haemost (11 Suppl 1):180–191, 2013.
9. Lijfering WM, Middeldorp S, Veeger NJ, et al: Risk of recurrent 25. Canonico M, Plu-Bureau G, Lowe GDO, et al: Hormone replacement
venous thrombosis in homozygous carriers and double heterozygous therapy and risk of venous thromboembolism in postmenopausal women:
carriers of factor V Leiden and prothrombin G20210A. Circulation systematic review and meta-analysis. BMJ 336(7655):1227–1231, 2008.
121(15):1706–1712, 2010. 26. Kearon C, Spencer FA, O’Keeffe D, et al: D-dimer testing to select
10. van der Meer FJ, Koster T, Vandebroucke JP, et al: The Leiden Throm- patients with a first unprovoked venous thromboembolism who can stop
bophilia Study (LETS). Thromb Haemost 78:631, 1997. anticoagulant therapy: a cohort study. Ann Intern Med 162(1):27–34,
11. Miyakis S, Lockshin MD, Atsumi T, et al: International consensus 2015.
statement on an update of the classification criteria for definite antiphos- 27. van der Hulle T, Tan M, den Exter PL, et al: Recurrence risk after
pholipid syndrome (APS). J Thromb Haemost 4:295, 2006. anticoagulant treatment of limited duration for late, second venous
12. Favaloro EJ, Wong RCW: Antiphospholipid antibody testing for the thromboembolism. Haematologica 100(2):188–193, 2015.
antiphospholipid syndrome: a comprehensive practical review including 28. Rodger MA, Kahn SR, Wells PS, et al: Identifying unprovoked throm-
a synopsis of challenges and recent guidelines. Pathology 46(6):481–495, boembolism patients at low risk for recurrence who can discontinue
2014. anticoagulant therapy. CMAJ 179(5):417–426, 2008.
13. Pengo V, Tripodi A, Reber G, et al: Update of the guidelines for lupus 29. Lee AYY, Levine MN, Baker RI, et al: Low-molecular-weight heparin
anticoagulant detection. Subcommittee on Lupus Anticoagulant/ versus a coumarin for the prevention of recurrent venous thromboem-
Antiphospholipid Antibody of the Scientific and Standardisation Com- bolism in patients with cancer. N Engl J Med 349:146, 2003.
mittee of the International Society on Thrombosis and Haemostasis. J 30. Bates SM, Greer IA, Middeldorp S, et al: VTE, thrombophilia,
Thromb Haemost 7(10):1737–1740, 2009. antithrombotic therapy, and pregnancy: antithrombotic therapy and
14. Devreese KM, Pierangeli SS, de Laat B, et al: Testing for antiphospho- prevention of thrombosis, 9th ed: American college of chest physicians
lipid antibodies with solid phase assays: guidance from the SSC of the evidence-based clinical practice guidelines. Chest 141(2 Suppl):e691S–
ISTH. J Thromb Haemost 12(5):792–795, 2014. e736S, 2012.